Sol-Gel Announces the Signing of Six Exclusive License Agreements to Commercialize TWYNEO® and EPSOLAY® in Europe and South Africa
July 25, 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel Announces the Signing of Six Exclusive License Agreements to Commercialize TWYNEO® and EPSOLAY® in Europe and South Africa
Sol-Gel Technologies Announces Management Realignment
July 15, 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel Technologies Announces Management Realignment
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
April 01, 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments
March 13, 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel Reports Full Year 2023 Financial Results and Corporate Developments
HC2 Holdings Portfolio Company R2 Technologies Receives Final Tranche of $30 Million Investment
February 03, 2021 08:45 ET
|
HC2 Holdings, Inc.
NEW YORK, Feb. 03, 2021 (GLOBE NEWSWIRE) -- HC2 Holdings, Inc. (“HC2” or “the Company”) (NYSE: HCHC) today announced that R2 Technologies Inc. ("R2"), founded by HC2’s portfolio company Pansend Life...
Glacial Rx™ System Named Among ‘2021 Launches Doctors are Buzzing About’
January 05, 2021 07:00 ET
|
HC2 Holdings, Inc.
R2 Technologies - founded by HC2’s portfolio company Pansend Life Sciences - Offers Innovation in Skin Resurfacing with FDA-Approved Cryo-Based Technology R2 Technologies seeks to capture a...